MENU
Antidote is a digital health company on a mission. Our aim is to accelerate the breakthroughs of potentially life-saving treatments, by bridging the gap between medical research and the people who need it. Our company is founded on the belief that every patient should be aware of every treatment option available to them. This includes clinical trials, where potential cures are being developed and tested.
We have taken on the massive job of making all publicly available clinical trial information machine-readable and searchable. This means that for the first time, using our search tool, Antidote Match™, patients can answer just a few questions to search through thousands of trials in seconds and find one that’s right for them.
Antidote gives researchers like you the opportunity to provide details that patients want and need when making clinical trial decisions – in plain English. With Antidote Bridge™, researchers can provide additional information on everything from procedures used to number of overnight stays, and from placebo use to financial compensation. We know that most of the time, it’s these details that matter most to patients selecting a clinical trial. Inputting this information only takes a few minutes and goes far to improve patient engagement.
Bridge allows Antidote to structure information about your trial that matters to patients in a consistent and easy-to-read manner. We use the information listed on ClinicalTrials.gov as a starting point, but Bridge allows you to create a more patient-friendly study page.
Antidote automatically creates a study page for open (recruiting, not yet recruiting, expanded access available) trials that are listed on ClinicalTrials.gov.
Any open (recruiting, not yet recruiting, expanded access available) trial listed on ClinicalTrials.gov can be enhanced. You can enhance any and all studies for which your organization is the lead sponsor, or for which the lead sponsor has given approval, and for which you have been granted editing permission. In order to publish (make public) the enhanced study page, you will also need publishing permission.
Only people with access to a particular lead sponsor’s trials will be able to view the trial in a list of search results. Only people given editing access for a particular lead sponsor will be able to edit the lead sponsor’s trials. Only people given publishing access for a particular lead sponsor will be able to publish the lead sponsor’s trials.
The trials you choose to enhance are up to you. Of course, our goal is to provide the largest amount of patient-friendly information, so we encourage you to enhance as many trials as possible.
You are certainly welcome to delegate tasks or studies to CROs with which you work. Please contact us at hello@antidote.me and we will work with you to determine who is authorized to enhance your studies.
No. Bridge only updates the information that appears on the Antidote study page; the ClinicalTrials.gov listing will be unaffected.
The following information is gathered from ClinicalTrials.gov and shown on the Antidote study pages by default:
The following information gathered from ClinicalTrials.gov can be reviewed and updated on the Antidote study page using Bridge:
Remember that the information provided on Bridge will only be visible on the Antidote study page, and the information on the ClinicalTrials.gov page is never updated or changed by using Bridge.
The following information can be added to the study page via Bridge:
The information we ask you to add through Bridge is that which we’ve found is important to patients. Patients don't just care about the title and purpose of the trial – they are interested in the practical details about what their participation will look like and how it will affect their daily lives. That’s why we ask you to provide information on the number of hospital visits and overnight stays, the types of procedures that will be done, the financial compensation, and whether patients will have access to the drug after the trial. This type of logistical information is freely shared during the Informed Consent Process. This is your opportunity to help patients more richly understand your study in their context.
Yes. Antidote study pages are automatically updated within 24 hours of an update to study information on ClinicalTrials.gov.
Once published, the information you have provided via Bridge will be added to the Antidote study page for your trial. This study page will be accessible via the antidote.me search tools and through our partner network.
All questions are optional. You are free to answer or skip as many questions as you like. But, the more information you provide, the better for patients.
We will be continuously looking to extend the options for enhancing trials. If you have suggestions of additional fields or options that should be added, we’d love to hear them. Please email hello@antidote.me.
We have kept potential answers succinct in order to keep study pages as patient-friendly and easy-to-read as possible. If you feel your answer needs caveats, you can skip that field, or pick your best case. Please also send your feedback to hello@antidote.me. Currently, additional information cannot be displayed on our study page, but your feedback will help us plan future developments.
Currently, the site-level contact information cannot be updated using Bridge. However, we will use the latest site contact information on ClinicalTrials.gov, so if you make changes there, your Antidote study page will be updated within 24 hours.
No. By entering the information in Bridge, you are not automatically making the information public. It is saved as a draft until you authorize it to be published.
Once your trial’s information has been entered into Bridge in draft format, you can “preview” online before publishing. Your data will only be made public after you “publish.”
No. It is the user’s responsibility to ensure that the enhancements made via Bridge are correct. We do not verify that the answers provided are correct for the trial in question.
Bridge has been designed with the assistance and approval of Chesapeake IRB. If you edit free text fields (e.g., title and purpose) you may require additional approval if not using pre-approved language. Each sponsor has different interpretation and processes for sharing of data and IRB approvals. Check with your company for alignment to their standard operating procedures.
No. Antidote is free for patients to use, and registration is not required.
No, patient enrollment that happens through Bridge is free of cost. Separate from Bridge, we do offer premium trial services, including customized marketing campaigns and referral management, for which we charge on a pay-for-performance model. For more information on premium trial services, email hello@antidote.me.
Bridge is largely a patient engagement tool, which improves your odds of enrolling patients in your studies.
If your trial needs a boost, we do offer more proactive recruitment services, through which we work with you to develop customized marketing campaigns to target relevant audiences through search engines, social media, and custom content on our partner network. We charge for these services on a pay-for-performance model. For more information on premium trial services, email hello@antidote.me.
Enhancing your trial on Bridge is certainly a great first step. If you’re looking for patient-friendly clinical trials information, please visit How It Works for some excellent resources on clinical trials that speak directly to patients.
For more information on Antidote’s premium services, please visit Services or email hello@antidote.me.
At Antidote, we believe that protecting patient privacy is absolutely essential. Patients can use our site knowing that we use the best technology to secure the health information they are sharing. For more information, please view our Privacy Policy.
Terms and conditions can be found here. To request a pdf copy of the Terms and Conditions, email hello@antidote.me.
